Death receptor-independent FADD signalling triggers hepatitis and hepatocellular carcinoma in mice with liver parenchymal cell-specific NEMO knockout

Cell Death and Differentiation

Volumn 21, Issue 11, 2014, Pages 1721-1732

  Ehlken, H ^a,b   Krishna Subramanian, S ^a   Ochoa Callejero, L ^a,c   Kondylis, V ^a   Nadi, N E ^a   Straub, B K ^d   Schirmacher, P ^d   Walczak, H ^e   Kollias, G ^f   Pasparakis, M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c CENTER FOR BIOMEDICAL RESEARCH OF LA RIOJA CIBIR   (Spain)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR; FADD PROTEIN, MOUSE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEMO PROTEIN, MOUSE; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; GENETICS; HEPATITIS; IMMUNOLOGY; KNOCKOUT MOUSE; LIVER NEOPLASMS; METABOLISM; MOUSE; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HEPATITIS; I-KAPPA B KINASE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MICE; MICE, KNOCKOUT; NF-KAPPA B; RECEPTORS, DEATH DOMAIN; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I;

EID: 84932174753     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.83     Document Type: Article

References (36)

1. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Exp Rev Gastroenterol Hepatol 2009; 3: 353-367.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
3. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol 2012; 56: 704-713.
4. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011; 12: 715-723.
5. Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012; 26: 203-234.
6. Luedde T, Schwabe RF. NF-kappaB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8: 108-118.
7. Sun B, Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 2008; 27: 6228-6244.
8. Luedde T, Heinrichsdorff J, de Lorenzi R, De Vos R, Roskams T, Pasparakis M. IKK1 and IKK2 cooperate to maintain bile duct integrity in the liver. Proc Natl Acad Sci USA 2008; 105: 9733-9738.
9. Makris C, Godfrey VL, Krahn-Senftleben G, Takahashi T, Roberts JL, Schwarz T et al. Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol Cell 2000; 5: 969-979.
10. Schmidt-Supprian M, Bloch W, Courtois G, Addicks K, Israel A, Rajewsky K et al. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol Cell 2000; 5: 981-992.
11. Rudolph D, Yeh W, Wakeham A, Rudolph B, Nallainathan D, Potter J et al. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev 2000; 14: 854-862.
12. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-466.
13. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16: 295-308.
14. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-990.
15. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer cell 2007; 11: 119-132.
16. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
17. Liedtke C, Bangen JM, Freimuth J, Beraza N, Lambertz D, Cubero FJ et al. Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology 2011; 141: 2176-2187.
18. Bonnet MC, Preukschat D, Welz PS, van Loo G, Ermolaeva MA, Bloch W et al. The adaptor protein FADD protects epidermal keratinocytes from necroptosis in vivo and prevents skin inflammation. Immunity 2011; 35: 572-582.
19. Welz PS, Wullaert A, Vlantis K, Kondylis V, Fernandez-Majada V, Ermolaeva M et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 2011; 477: 330-334.
20. Zhang H, Zhou X, McQuade T, Li J, Chan FK, Zhang J. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 2011; 471: 373-376.
21. Doi T, Marino M, Takahashi T, Yoshida T, Sakakura T, Old L et al. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci USA 1999; 96: 2994-2999.
22. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 1999; 284: 321-325.
23. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996; 184: 1397-1411.
24. Beraza N, Malato Y, Sander L, Al-Masaoudi M, Freimuth J, Riethmacher D et al. Hepatocyte-specific NEMO deletion promotes NK/NKT cell-and TRAIL-dependent liver damage. J Exp Med 2009; 206: 1727-1737.
25. Wang K. Molecular mechanisms of hepatic apoptosis. Cell Death Dis 2014; 5: e996.
26. Schattenberg JM, Schuchmann M, Galle PR. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. J Gastroenterol Hepatol 2011; 26(Suppl 1): 213-219.
27. Pasparakis M. Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol 2009; 9: 778-788.
28. Liedtke C, Bangen J-M, Freimuth J, Beraza N, Lambertz D, Cubero F et al. Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology 2011; 141: 2176-2187.
29. Cubero F, Singh A, Borkham-Kamphorst E, Nevzorova Y, Al Masaoudi M, Haas U et al. TNFR1 determines progression of chronic liver injury in the IKKg/Nemo genetic model. Cell Death Differ 2013; 20: 1580-1592.
30. Meylan F, Richard AC, RM. Siegel. TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol Rev 2011; 244: 188-196.
31. Kellendonk C, Opherk C, Anlag K, Schü tz G, Tronche F. Hepatocyte-specific expression of Cre recombinase. Genesis 2000; 26: 151-153.
32. Mc Guire C, Volckaert T, Wolke U, Sze M, de Rycke R, Waisman A et al. Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination. J Immunol 2010; 185: 7646-7653.
33. Van Hauwermeiren F, Armaka M, Karagianni N, Kranidioti K, Vandenbroucke R, Loges S et al. Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium. J Clin Invest 2013; 123: 2590-2603.
34. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008; 118: 100-110.
35. Hao Z, Hampel B, Yagita H, Rajewsky K. T cell-specific ablation of Fas leads to Fas ligandmediated lymphocyte depletion and inflammatory pulmonary fibrosis. J Exp Med 2004; 199: 1355-1365.
36. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68: 869-877.